Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease

Watson, Philip; Turner, David P. J.

doi:10.1016/j.vaccine.2015.11.057

Cited by 61 publications

(49 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis, however, was too small to conclude whether the vaccine had provided protection against the outbreak strain. Bexsero has also been used in targeted immunization campaigns at the University of California, Santa Barbara and in the Saguenay–Lac-Saint-Jean region of Quebec (26). …”

Section: Vaccines For Protection Against Serogroup B Meningococcimentioning

confidence: 99%

“…Notwithstanding the various challenges associated with the SBA bioassay, it has played an important part in the clinical assessment of Bexsero and Trumenba, and the resulting immunogenicity data used for licensure have been reviewed extensively elsewhere (26, 44, 45). For each of the vaccines, the assay was applied to distinct panels of reference meningococcal isolates, which reflect their different components.…”

Section: Vaccine Antigen Coverage Antibody Persistence and Agementioning

confidence: 99%

See 1 more Smart Citation

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Feavers

Maiden

2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of 4 decades, vaccine development has focused on subcapsular protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies, and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations. As a result, evidence of the effectiveness of these vaccines against different strains and the contribution of specific antigens to protection can only be provided by epidemiological analyses following their implementation in sufficiently large populations. The recent inclusion of the four-component meningococcal serogroup B (4CMenB) vaccine, Bexsero, in the infant immunization program in the UK has provided preliminary evidence that the vaccine is effective. Ongoing surveillance will provide valuable data on its longer-term impact and antigenic coverage. Further development of protein-based vaccines against meningococcal disease is anticipated to improve antigenic coverage and adjust to changes in circulating strains. At the same time, alternative immunization strategies may be explored to improve overall vaccine effectiveness by, for example, protecting the youngest infants or providing herd protection.

show abstract

Section: Vaccines For Protection Against Serogroup B Meningococcimentioning

confidence: 99%

Section: Vaccine Antigen Coverage Antibody Persistence and Agementioning

confidence: 99%

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Feavers

Maiden

2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…In the final subunit vaccine, BEXSERO ® , three proteins were selected for incorporation, (i.e., Factor H binding protein, Neisserial adhesion A, and Niesseria heparin binding antigen) along with a detergent extracted outer membrane vesicle (DOMV). The BEXSERO ® vaccine is now licensed in over 35 countries and has already had an impact on the mortality and morbidity associated with N meningitidis serogroup B [7]. …”

Section: Introductionmentioning

confidence: 99%

Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology

Heinson

Gunawardana

Moesker

et al. 2017

IJMS

View full text Add to dashboard Cite

Reverse vaccinology (RV) is a bioinformatics approach that can predict antigens with protective potential from the protein coding genomes of bacterial pathogens for subunit vaccine design. RV has become firmly established following the development of the BEXSERO® vaccine against Neisseria meningitidis serogroup B. RV studies have begun to incorporate machine learning (ML) techniques to distinguish bacterial protective antigens (BPAs) from non-BPAs. This research contributes significantly to the RV field by using permutation analysis to demonstrate that a signal for protective antigens can be curated from published data. Furthermore, the effects of the following on an ML approach to RV were also assessed: nested cross-validation, balancing selection of non-BPAs for subcellular localization, increasing the training data, and incorporating greater numbers of protein annotation tools for feature generation. These enhancements yielded a support vector machine (SVM) classifier that could discriminate BPAs (n = 200) from non-BPAs (n = 200) with an area under the curve (AUC) of 0.787. In addition, hierarchical clustering of BPAs revealed that intracellular BPAs clustered separately from extracellular BPAs. However, no immediate benefit was derived when training SVM classifiers on data sets exclusively containing intra- or extracellular BPAs. In conclusion, this work demonstrates that ML classifiers have great utility in RV approaches and will lead to new subunit vaccines in the future.

show abstract

“…76 In contrast to what expected in the technical datasheet, the proposed schedule provides two doses with a booster at 12 months in order to prevent antibodies waning. 77 In the United States (USA), another new vaccine was recently approved by the Food and Drugs Administration (FDA) for use in persons aged 10-25 years: MenB-FHbp. 78 As it induces high fever in infants, it is not recommended for use in children under 10 years of age.…”

Section: Discussionmentioning

confidence: 99%

Meningococcal B vaccination: real-world experience and future perspectives

Kuhdari

Stefanati

Lupi

et al. 2016

Pathogens and Global Health

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) represents a severe risk for health. It can be considered the most dangerous vaccine-preventable disease due to the high probability of related permanent sequelae and death. The introduction in many countries of the conjugate vaccines against A, C, W135, and Y meningococcal serogroups influenced significantly the impact of the disease. Recently, the difficulties in obtaining an effective vaccine against meningococcal serogroup B (MenB) have been get over through the reverse vaccinology, enabling the recognition of some antigens providing a response against most of circulating MenB strains worldwide. The new 4cMenB vaccine is recommended in Europe, Canada, Australia, the USA, and some Latin American countries. Even if sound data on efficacy and safety profile are available, the results in terms of effectiveness are still limited. The management of the MenB outbreaks in two US universities demonstrated the ability to quickly achieve high vaccination coverage rates and no new cases among immunized subjects were assessed. It is desirable that the opportunity to complete preventive intervention against IMD offered by the new 4cMenB vaccine should be recognized and that this vaccine is included in the vaccination schedule to complete the panel of immunization against Neisseria meningitidis.

show abstract

Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease

Cited by 61 publications

References 43 publications

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology

Meningococcal B vaccination: real-world experience and future perspectives

Contact Info

Product

Resources

About